Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas

Reuters

10/20

Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas

Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate $(ADC)$, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576007101"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576007101\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576007101?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 08:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576007101","market":"us","top_or_hot":-1,"title":"Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 08:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL7gbp5W:1","article_id":"2576007101","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576007101","pubTimestamp":1760920554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate , in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma , the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"豪森制药报告HS-20093治疗复发性或难治性肉瘤的2期结果令人鼓舞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate $(ADC)$, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}